Systemic Lupus Erythematous SLE Drugs Market
Market Insights on Systemic Lupus Erythematous SLE Drugs covering sales outlook, demand forecast & up-to-date key trends
Systemic Lupus Erythematous SLE Drugs Market by Product, Application & Region - Forecast 2022 to 2032
Systemic Lupus Erythematous SLE Drugs Market Overview (2022-2032)
[250 Pages Report] The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Bn in 2020, to reach a valuation of US$ 329.18 Bn by 2032.
The systemic lupus erythematosus (SLE) drugs market is anticipated to show promising growth prospects owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).
|
Attributes |
Details |
|
Systemic Lupus Erythematosus (SLE) Drugs Market Value (2020) |
US$ 183.3 Bn |
|
Systemic Lupus Erythematosus (SLE) Drugs Market (2032) |
US$ 329.18 Bn |
|
CAGR (2022-2032) |
5% |
Sales of systemic lupus erythematosus (SLE) drugs is expected to rise with the introduction of novel biological therapies in the development pipeline. In addition to this, demand for systemic lupus erythematosus (SLE) drugs is rising due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE).
This factor is anticipated to significantly influence the systemic lupus erythematosus (SLE) drugs market, as over 50% of SLE patients have lupus nephritis.
Some new potential medications in Phase III studies are also projected to contribute to the growth of the systemic lupus erythematosus (SLE) drugs market share.
Some of the key systemic lupus erythematosus (SLE) drugs trends promoting the demand for systemic lupus erythematosus (SLE) drugs market include clinicians only administering biologics when two or more non-biologic immunosuppressants have failed to ameliorate a patient's disease activity.
Several nations have developed payment schemes based on these criteria, which greatly boosted the sales of systemic lupus erythematosus (SLE) drugs.
In developed nations, demand for systemic lupus erythematosus (SLE) drugs is higher due to stronger healthcare infrastructure and coverage availability. In underdeveloped regions, high costs and a lack of government-funded coverage limit access to biologics.
Let us know your requirement to get
100% FREE customization
What are the Key Contributors to the Systemic Lupus Erythematosus (SLE) Drugs Market Share?
The global market for systemic lupus erythematosus (SLE) drugs is expected to expand due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE). The development of newer SLE medicines increased availability of biosimilar pharmaceuticals, and increased support for developing research areas for new drug molecules are increasing the sales of systemic lupus erythematosus (SLE) drugs and propelling the global systemic lupus erythematosus (SLE) drugs market forward.
Increased awareness of illness diagnosis and treatment and constant research and development procedures for innovative therapeutic molecules are major drivers of the global systemic lupus erythematosus (SLE) drugs. Furthermore, the safety and quality of systemic lupus erythematous controlling therapy may provide a hurdle to the sales of systemic lupus erythematosus (SLE) drugs.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Region holds the Highest Growth Potential in the Systemic Lupus Erythematosus (SLE) Drugs Market?
Global systemic lupus erythematosus (SLE) drugs market growth is fast in the North American region and is estimated to project remarkable CAGR growth throughout the forecast period.
In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans, according to the Centers for Disease Control and Prevention (CDC). It is anticipated that this factor will boost the demand for systemic lupus erythematosus (SLE) drugs in the region.
The second-largest and fastest-growing systemic lupus erythematosus (SLE) drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double-digit CAGR due to the higher prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of systemic lupus erythematosus (SLE) drugs.
This is expected to be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy, Spain, the UK and Japan. Benlysta will lead sales of systemic lupus erythematosus (SLE) drugs in coming years because of its excellent safety profile as well as proven efficacy in clinical trials.
Who are the Key Players in the Systemic Lupus Erythematosus (SLE) Drugs Market?
The key players in the global systemic lupus erythematous drugs market are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
Recent Developments
- Hydroxychloroquine, the last drug, was approved by the FDA in 1955 for SLE treatment.
- Recently, a drug called belimumab was approved by FDA after 50 years long gap specifically for SLE, on March 9, 2011. It is the first-ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc.
- In collaboration with GlaxoSmithKline, Benlysta is anticipated to lead systemic lupus erythematosus (SLE) drugs market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials.
- NSAIDs such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment
A unified Market Research Subscription Platform, built for today's disparate research needs.
Scope of Report
|
Report Attribute |
Details |
|
Growth rate |
CAGR of 5% from 2022 to 2032 |
|
Base year for estimation |
2021 |
|
Historical data |
2015 - 2020 |
|
Forecast period |
2022 - 2032 |
|
Quantitative units |
Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032 |
|
Report coverage |
Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
|
Segments covered |
Drug Classes, Route of Administration, region |
|
Regional scope |
North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
|
Country scope |
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
|
Key companies profiled |
Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries. |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. |
Key Segments
By Drug Classes:
- NSAIDs
- Corticosteroids
- Antimalarials
- Immunosuppresants
- Biologics
By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
The systemic lupus erythematous (SLE) drugs market is likely to register a CAGR of 5% during the forecast period (2022-2032).
Key players holding substantial systemic lupus erythematous (SLE) drugs market share include Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
As per the analysis, the systemic lupus erythematous (SLE) drugs market is likely to be US$ 329 Bn by 2032.
Demand for systemic lupus erythematous (SLE) drugs is likely to rise owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Molecule Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Molecule Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Molecule Type, 2022-2032
5.3.1. Corticosteroids
5.3.2. Non-Steroidal Anti-inflammatory Drugs
5.3.3. Disease-Modifying Anti-Rheumatic Drugs
5.3.4. Antimalarial Drugs
5.3.5. BLyS-specific Inhibitors or Monoclonal Antibodies
5.3.6. Immunosuppressive Agents/Immune Modulators
5.3.7. Anticoagulants
5.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Molecule Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores
6.3.3. Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia & Pacific
7.3.6. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.K.
8.2.1.2. Canada
8.2.2. By Molecule Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Molecule Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Molecule Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Molecule Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Molecule Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Molecule Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Molecule Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Molecule Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Indonesia
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. New Zealand
12.2.1.8. Rest of South Asia & Pacific
12.2.2. By Molecule Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Molecule Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Molecule Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Molecule Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.K.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Molecule Type
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Molecule Type
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Molecule Type
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Molecule Type
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Molecule Type
14.5.2.2. By Distribution Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Molecule Type
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Molecule Type
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Molecule Type
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Molecule Type
14.9.2.2. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Molecule Type
14.10.2.2. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Molecule Type
14.11.2.2. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Molecule Type
14.12.2.2. By Distribution Channel
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Molecule Type
14.13.2.2. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Molecule Type
14.14.2.2. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Molecule Type
14.15.2.2. By Distribution Channel
14.16. Malaysia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Molecule Type
14.16.2.2. By Distribution Channel
14.17. Singapore
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Molecule Type
14.17.2.2. By Distribution Channel
14.18. Australia
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Molecule Type
14.18.2.2. By Distribution Channel
14.19. New Zealand
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Molecule Type
14.19.2.2. By Distribution Channel
14.20. GCC Countries
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Molecule Type
14.20.2.2. By Distribution Channel
14.21. South Africa
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Molecule Type
14.21.2.2. By Distribution Channel
14.22. Israel
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Molecule Type
14.22.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Molecule Type
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Anthera Pharmaceuticals
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. GlaxoSmithKline Pharmaceuticals Limited
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. ImmuPharma PLC
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Merck Serono
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Johnson & Johnson Private Limited
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Novartis AG
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. MedImmune
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sanofi
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Teva Pharmaceutical Industries
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. HGS
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 3: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 4: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 5: North America Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 6: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Latin America Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 9: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 12: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 13: East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: East Asia Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 15: East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 16: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: South Asia & Pacific Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 18: South Asia & Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 19: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 20: MEA Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
Table 21: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 3: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 8: Global Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 9: Global Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 10: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 13: Global Market Attractiveness by Molecule Type, 2022-2032
Figure 14: Global Market Attractiveness by Distribution Channel, 2022-2032
Figure 15: Global Market Attractiveness by Region, 2022-2032
Figure 16: North America Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 17: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 28: North America Market Attractiveness by Molecule Type, 2022-2032
Figure 29: North America Market Attractiveness by Distribution Channel, 2022-2032
Figure 30: North America Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 32: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 40: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 43: Latin America Market Attractiveness by Molecule Type, 2022-2032
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2022-2032
Figure 45: Latin America Market Attractiveness by Country, 2022-2032
Figure 46: Europe Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 47: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 55: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 58: Europe Market Attractiveness by Molecule Type, 2022-2032
Figure 59: Europe Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Europe Market Attractiveness by Country, 2022-2032
Figure 61: East Asia Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 62: East Asia Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 63: East Asia Market Value (US$ Mn) by Country, 2022-2032
Figure 64: East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: East Asia Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 68: East Asia Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 69: East Asia Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 70: East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 71: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 72: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 73: East Asia Market Attractiveness by Molecule Type, 2022-2032
Figure 74: East Asia Market Attractiveness by Distribution Channel, 2022-2032
Figure 75: East Asia Market Attractiveness by Country, 2022-2032
Figure 76: South Asia & Pacific Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 77: South Asia & Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 78: South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 79: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: South Asia & Pacific Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 83: South Asia & Pacific Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 84: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 85: South Asia & Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 86: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 87: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 88: South Asia & Pacific Market Attractiveness by Molecule Type, 2022-2032
Figure 89: South Asia & Pacific Market Attractiveness by Distribution Channel, 2022-2032
Figure 90: South Asia & Pacific Market Attractiveness by Country, 2022-2032
Figure 91: MEA Market Value (US$ Mn) by Molecule Type, 2022-2032
Figure 92: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 93: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 94: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 95: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 96: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 97: MEA Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
Figure 98: MEA Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
Figure 99: MEA Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
Figure 100: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 101: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 102: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 103: MEA Market Attractiveness by Molecule Type, 2022-2032
Figure 104: MEA Market Attractiveness by Distribution Channel, 2022-2032
Figure 105: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
